Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
about
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Comparison of the effects of low dose interferon and high dose interferon on reduction of the number and size of plaques in patients with Multiple Sclerosis: A historical cohort.Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosisTranscriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Effects of immunomodulators on the response induced by vaccines against autoimmune diseases.In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.The therapeutic potential of Rho kinase inhibitor fasudil derivative FaD-1 in experimental autoimmune encephalomyelitis.Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Gene Therapy for Autoimmune Disease.HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
P2860
Q33742905-4880F634-54EF-4958-91E6-C47BEC0B198BQ33896802-E1726A5E-7FAA-4DF8-96A6-F1AE9FDA1E68Q34355672-42F489D2-1216-4845-8080-23FFF3B5ACF5Q35847422-F236FCE5-0850-42FD-ADF8-BB4681B824D5Q36092690-6DEEBD7C-6056-44CA-980D-5BF645878E66Q38218692-78664370-FE7B-491E-B5C5-681E29076E89Q38449394-AE1FBFB3-DC31-46C5-8125-9E17D8D530B2Q38910574-0C56DA14-C1E0-41C6-8A9C-8FADFA9D2222Q40046753-385C5658-5DA7-4CD0-9555-D520A318FAD1Q42371905-87A0DDAF-A768-41B7-B7A7-E4C200A5D450Q47639943-FE5F1EC1-7198-4682-8C71-77C8F1EA0D4EQ48541667-018E1AA3-5676-465A-93F5-340CA8DD2C5BQ51089837-B72CA6AC-0FDE-440C-916D-D83AC7A6B520Q52897470-0974D5EE-7BF0-4803-B5BF-5A156D4CC7FDQ53014578-33DBFBA1-5010-463E-9CE2-499A249796CCQ53165441-58C4AC54-0E8E-4914-9AF9-97CE8049F05A
P2860
Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacogenomics of interferon ...... e: a review of the literature.
@ast
Pharmacogenomics of interferon ...... e: a review of the literature.
@en
type
label
Pharmacogenomics of interferon ...... e: a review of the literature.
@ast
Pharmacogenomics of interferon ...... e: a review of the literature.
@en
prefLabel
Pharmacogenomics of interferon ...... e: a review of the literature.
@ast
Pharmacogenomics of interferon ...... e: a review of the literature.
@en
P1433
P1476
Pharmacogenomics of interferon ...... e: a review of the literature.
@en
P2093
Catherine O'Doherty
Sunil Mahurkar
P304
P356
10.1016/J.AUTREV.2013.10.012
P577
2013-11-02T00:00:00Z